Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-… Read more
Denali Therapeutics Inc (DNLI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.116x
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has a cash flow conversion efficiency ratio of -0.116x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-107.30 Million) by net assets ($926.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Denali Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Denali Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Denali Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Denali Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
0.027x |
|
HMT(Xiamen)New Technical
SHG:603306
|
0.018x |
|
Scotts Miracle-Gro Company
NYSE:SMG
|
-0.487x |
|
Zhejiang CFMoto Power Co Ltd
SHG:603129
|
0.109x |
|
Jiangxi Lianchuang Opto-electronic Science & Technology Co Ltd
SHG:600363
|
0.012x |
|
Centre Testing Intl Shenzhen
SHE:300012
|
0.056x |
|
Zhejiang Wanfeng Auto Wheel Co Ltd
SHE:002085
|
0.006x |
|
SGHC Limited
NYSE:SGHC
|
0.004x |
Annual Cash Flow Conversion Efficiency for Denali Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.23 Billion | $-347.69 Million | -0.283x | +18.57% |
| 2023-12-31 | $1.03 Billion | $-357.99 Million | -0.347x | -47.92% |
| 2022-12-31 | $1.04 Billion | $-244.72 Million | -0.235x | -6.87% |
| 2021-12-31 | $962.29 Million | $-211.39 Million | -0.220x | -160.73% |
| 2020-12-31 | $1.15 Billion | $416.15 Million | 0.362x | +194.23% |
| 2019-12-31 | $394.89 Million | $-151.58 Million | -0.384x | -518.83% |
| 2018-12-31 | $546.85 Million | $50.12 Million | 0.092x | +155.70% |
| 2017-12-31 | $465.80 Million | $-76.64 Million | -0.165x | +42.13% |
| 2016-12-31 | $254.52 Million | $-72.36 Million | -0.284x | -129.53% |
| 2015-12-31 | $-15.63 Million | $-15.05 Million | 0.963x | -- |